ClinicalTrials.gg
CompletedNCT02841995Updated Jun 28, 2023Results posted

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

A Phase 2 interventional study of Belumosudil (KD025) in Graft vs Host Disease, sponsored by Kadmon, a Sanofi Company. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Kadmon, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
97th of 389
54 · median 30
Started
2016
with 15 others
Phase 2
164 of 454
15 open now
Registered
311th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 97th largest by enrollment of the 389 interventional ones that give a count, is one of 16 that started in 2016, is one of 164 in phase 2, and was the 311th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).

Read the detailed description

Fifty four (54) participants were enrolled to receive orally administered belumosudil 200 milligrams (mg) once daily (QD), belumosudil 200 mg twice daily (BID), or belumosudil 400 mg QD.

Study drug was administered in 28-day cycles until disease progression or occurrence of unacceptable toxicity. Participants received study drug in the inpatient or outpatient setting.

03

Conditions studied

  • Graft vs Host Disease

Keywords

  • cGVHD
  • Allogeneic hematopoietic stem cell transplantation
  • Immune System Diseases
  • Steroid refractory chronic graft vs host disease (cGVHD)
  • Bone Marrow Transplantation
  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Corticosteroids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male and female participants at least 18 years of age who had allogenic bone marrow transplant (BMT) or hematopoietic stem cell transplantation ().
  • Received therapy and calcineurin therapy or glucocorticoid therapy alone for cGVHD at study entry. Participants on calcineurin therapy only, without glucocorticoid therapy, were not eligible. Participants also received other therapies thought not to be (such as extracorporeal photopheresis; ECP), were considered for enrollment in this study on a case-by-case basis.
  • Had persistent active cGVHD manifestations, as defined by 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD, after at least 2 months of steroid therapy.
  • No more than 3 for cGVHD.
  • Performance Scale of greater than (>) 40.
  • Adequate organ and bone marrow functions evaluated during the 14 days prior to enrollment as follows:

    • greater than or equal to (>=) 1.5*10\^9/L (without myeloid growth factors within 1 week of study entry)
    • count >=50*10\^9/L (without transfusion or thrombopoietin or thrombopoietin analogues within 2 weeks of study entry)
  • Adequate safety laboratory values:

    • Total less than or equal to (\<=) 1.5* (ULN)
    • and aspartate aminotransferase \<=3*ULN
    • (GFR) >= 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) using the 4-Variable Modification of Diet in Renal Disease variable formula
  • Female participants of have a negative pregnancy test at screening. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had any evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, anti estrogens, or ovarian suppression.
  • Women of childbearing potential (i.e., menstruating women) must had a negative urine pregnancy test (positive urine tests were to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
  • Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:

    • Intrauterine device plus one barrier method;
    • Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method;
    • 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or
    • A vasectomized partner
  • For male participants who were sexually active and who were partners of premenopausal women: agreement to use two forms of contraception as in criterion 10 above during the treatment period and for at least 3 months after the last dose of study drug.
  • Able to provide written prior to the performance of any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Female participant who was pregnant or breastfeeding.
  • Received an treatment within 28 days of study entry.
  • Had acute GVHD.
  • Taken any medication known to be a moderate or strong inhibitor of the cytochrome (CY) isozyme or any drugs that are moderate or strong CYP3A4 inducers.
  • History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease or coronary artery disease).
  • Regular and excessive use of alcohol within the 6 months prior to study entry defined as alcohol intake >14 drinks per week in a man or >7 drinks per week in a woman. Approximately 10 grams of alcohol equals one "drink" unit. One unit equals 1 ounce of distilled spirits, one 12-ounce beer, or one 4-ounce glass of wine.
  • Known history of (HIV) or active virus (HCV) or virus (HBV).
  • Diagnosed with another (other than malignancy for which transplant was performed) within 3 years of enrollment, with the exception of completely resected basal cell or squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection.
  • Relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
  • Had previous exposure to belumosudil or known allergy/sensitivity to belumosudil or any other Rho-associated protein kinase-2 inhibitor.
  • Taken other drugs for GVHD, including mammalian target of rapamycin inhibitors (Note: Only , calcineurin inhibitors, and ECP are acceptable).
  • interval using Fridericia's formula >450 milliseconds.
  • Female participant who was pregnant or breastfeeding.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Cohort 1: Belumosudil 200 mg QD

    Participants received belumosudil 200 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 64.2 months).

    Drug: Belumosudil (KD025)

  • Experimental
    Cohort 2: Belumosudil 200 mg BID

    Participants received belumosudil 200 mg orally BID in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 45.9 months).

    Drug: Belumosudil (KD025)

  • Experimental
    Cohort 3: Belumosudil 400 mg QD

    Participants received belumosudil 400 mg orally QD in each 28-day treatment cycle until disease progression, unacceptable toxicity, or death whichever occurred first (maximum duration: 49.2 months).

    Drug: Belumosudil (KD025)

Interventions

  • Pharmaceutical form: Capsules or Tablets Route of administration: Oral

    Also known as: SLx-2119, REZUROCK

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response (OR)

    OR was defined as the percentage of participants with complete response (CR) or partial response (PR). The OR determination of chronic graft versus host disease (cGVHD) was based on cGVHD response assessment performed by clinicians as per the 2014 National Institutes of Health (NIH) Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site. PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression was defined as the clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

    Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug up to 28 days after the last dose of study drug). TEAEs included both SAEs and non-SAEs.

    Time frame: From first dose of study drug up to 28 days after the last dose of study drug (maximum duration: up to 64.2 months)

Secondary outcomes

  1. Number of Participants With Best Overall Response (BOR)

    BOR was defined as the participants with either a CR or PR or lack of response (LOR), where LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). BOR was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site.

    Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)

  2. Number of Participants With Maximal Improvement From Baseline in Global Severity Rating (GSR) by Clinician-reported cGVHD Assessment

    The GSR assessment was performed by asking the participants to rate their disease severity of cGVHD symptoms on a 0 to 10-point numeric rating scale, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. The response was defined using scores from 9 organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI) track, lower GI tract, liver, lungs, and joints and fascia plus GSR. End of treatment (EOT) visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as lowest GSR score on scheduled visits minus GSR score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms. Only those categories in which at least 1 participant had data were reported.

    Time frame: From Baseline up to end of treatment (i.e., up to 64.2 months)

  3. Number of Participants With Maximal Improvement From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report

    cGVHD symptom severity was self-reported by participants. Participants were asked to rate their disease symptom severity over the last week on the following questions: skin itching at its worst, moth dryness at its worst, mouth pain at its worst, mouth sensitivity at its worst, main compliant on eyes, symptom severity on eyes. Severity rating was done on a 0 to 10-point numeric rating scare, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. EOT visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as the lowest symptom severity score on scheduled visits minus the symptom severity score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms.

    Time frame: From Baseline up to end of treatment (i.e., up to 64.2 months)

  4. Failure-free Survival (FFS)

    Failure-free survival was defined as the time (in months) from first dose of study drug to either the start of another new systemic treatment for cGVHD, relapse of the underlying disease or death. If no such events happened, FFS was censored by last response assessment or long term follow up assessment, whichever was the latest and available. Kaplan-Meier survival method was used for the analysis.

    Time frame: From first dose of study drug to either start of another new systemic treatment for cGVHD, relapse of the underlying disease or death or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)

  5. Change From Baseline in Corticosteroids Dose

    Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

    Time frame: Baseline up to end of treatment (i.e., anytime up to 64.2 months)

  6. Number of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage

    Calcineurin inhibitors included systemic tacrolimus and cyclosporine. Number of participants who took CNI at Baseline and had reduction and discontinuation in CNI use as compared to Baseline during the study are reported in this outcome measure. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

    Time frame: Baseline up to end of treatment (i.e., anytime up to 64.2 months)

  7. Duration of Response (DOR)

    The DOR was defined as the time (in weeks) from first documentation of response to the time of first documentation of deterioration from best response (e.g., CR to PR, or PR to LR). LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site. Kaplan-Meier was used for the analysis.

    Time frame: From the date of first response until documented disease progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)

  8. Time-to-Response (TTR)

    Time-to-response was measured as the time (in weeks) from first dose of study drug to the time of first documentation of response. Response was defined as the participants achieving a PR or CR at any post-baseline response assessment. Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site and PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: From first dose of study drug treatment to the time of first documentation of response or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)

  9. Percentage of Participants With Best Response in Each Individual Organ

    Best response was defined as the percentage of participants with CR or PR. Response was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site. Organ response assessment was performed on 9 individual organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, and joints and fascia and is reported in this outcome measure.

    Time frame: From date of randomization until disease progression or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)

  10. Overall Survival (OS)

    Overall survival was defined as the time (in months) from first dose of study drug to the death due to any reason. If there was no death, OS was censored by last visit, last long-term follow-up, or study cut-off date, whichever occurred first. Kaplan-Meier survival method was used for the analysis.

    Time frame: From first dose of study drug to date of death from any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)

  11. Time to Next Therapy (TTNT)

    The TTNT was defined as the time (in months) from first treatment to the time of new systemic cGVHD treatment. TTNT was censored by last response assessment or long term follow up assessment, whichever was earlier. Kaplan-Meier survival method was used for the analysis.

    Time frame: From time of first treatment to the time of new systemic cGVHD treatment or long term follow-up assessment, whichever occurred first (maximum duration: up to 64.2 months)

  12. Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points

    Lee cGVHD symptom scale, a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing better outcome. Score for each subscale was normalized to a score ranged from 0 to 100, where higher score=worse symptoms. An overall Lee cGvHD score was calculated as average of these 7 subscales and it ranged from 0 to 100, where a higher score = worse symptoms. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

    Time frame: Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26, 27,28,29,30,31,32,33,34,35,36,37, 38,39,40,41,42,43,44,45,46,47,48, 49, 50,51,52,53, 54,55, 56, 57,58,59,60,61,62,63,67 and EOT (i.e., anytime up to 64.2 months)

  13. Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Each Specified Time Points

    FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

    Time frame: Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27, 29,30,31,32,33,34,35,36,37,38, 39,40,41,43, 47,48,49,51,52,53, 54, 55,56, 57,58,60,61,62,63,67, EOT (i.e., anytime up to 64.2 months)

  14. Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Each Specified Time Points

    FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

    Time frame: Baseline, Day 1 of Cycles 2, 3,4, 5,6,7,8,9,10,11,12,13, 14,15,16,17,18,19,20,21,22,23,24,25,26, 27,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47, 48,49, 51,52,53,54, 55, 56,57,58,60,61, 62, 63,67, EOT (i.e., anytime up to 64.2 months)

  15. Change From Baseline in Percent Predicted Hemoglobin (HGB) Corrected Diffusing Capacity of Lung for Carbon Monoxide (DLco) at Each Specified Time Points

    DLco is a measurement of the ability of the lungs to transfer gases from the air to the blood. Change from baseline in diffusing capacity of the lung for carbon monoxide (percent predicted hemoglobin level corrected) was reported for this measure. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

    Time frame: Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13, 14,15,16,17,18,19,20,21,22,23,24,25,26,27, 29,31,32,33,34,35,36,37,39,40,41,43,47,49,51,53,55, 61, 62, 63, 67, EOT (i.e., anytime up to 64.2 Months)

  16. Change From Baseline in Percent Predicted Total Lung Capacity (TLC) at Each Specified Time Points

    TLC is the volume of air in the lungs upon the maximum effort of inspiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

    Time frame: Baseline, Day 1 of Cycles 2,3, 4, 5,6,7, 8, 9, 10,11,12,13, 14, 15, 16, 17, 18, 19, 20,21, 22,23,24, 25, 26, 27,29, 30, 31,32, 33, 34, 35,36, 37, 38,39, 40,41,43,47, 48, 49,51,52,53, 54,55,56,57,58, 60,61,62, 63, 67, EOT (i.e., anytime up to 64.2 Months)

  17. Change From Baseline in Percent Predicted Residual Volume (RV) at Each Specified Time Points

    RV is the volume of air remaining in the lungs after maximum forceful expiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

    Time frame: Baseline, Day 1 of Cycles 2, 3, 4,5, 6,7, 8, 9, 10, 11,12, 13, 14,15, 16,17, 18, 19,20, 21,22,23, 24, 25, 26,27, 29, 30, 31, 32, 33,34, 35,36, 37,38, 39, 40,41, 43,47, 48, 49,51,52,53, 54, 55,56,57, 58,60,61,62,63,67, EOT (i.e., anytime up to 64.2 Months)

  18. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)

    Cmax was the maximum observed plasma concentration, obtained by a non-compartmental analysis. Cmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.

    Time frame: Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1

  19. Pharmacokinetics: Time of the Maximum Observed Plasma Concentration (Tmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)

    Tmax was defined as time to reach maximum observed plasma concentration, obtained by a non-compartmental analysis. Tmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.

    Time frame: Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1

  20. Pharmacokinetics: The Area Under the Plasma Concentration Versus Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6hr) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)

    AUC0-6hr was defined as area under the plasma concentration versus time curve from time 0 to 6 hours post-dose, obtained by a non-compartmental analysis from the concentration-time data. AUC0-6hr data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.

    Time frame: Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1

07

Results

Posted Jun 28, 2023

Participant flow

The study was conducted at 7 active sites in the United States. A total of 64 participants were screened between 15 September 2016 and 08 March 2018, of which 10 participants were screen failures due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Started171621
Completed000
Not completed171621
Withdrew: Disease progression5118
Withdrew: Withdrawal by subject244
Withdrew: Adverse event201
Withdrew: Investigator decision201
Withdrew: Death002
Withdrew: Noncompliance to protocol100
Withdrew: Sponsor decision100
Withdrew: Other415

Outcome measures

PrimaryPercentage of Participants With Overall Response (OR)

OR was defined as the percentage of participants with complete response (CR) or partial response (PR). The OR determination of chronic graft versus host disease (cGVHD) was based on cGVHD response assessment performed by clinicians as per the 2014 National Institutes of Health (NIH) Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site. PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression was defined as the clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

Time frame:
From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response (OR)
percentage of participantsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Percentage of Participants With Overall Response (OR)64.7 (38.3 to 85.8)68.8 (41.3 to 89.0)57.1 (34.0 to 78.2)
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug up to 28 days after the last dose of study drug). TEAEs included both SAEs and non-SAEs.

Time frame:
From first dose of study drug up to 28 days after the last dose of study drug (maximum duration: up to 64.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
TEAE171620
TESAE5613
SecondaryNumber of Participants With Best Overall Response (BOR)

BOR was defined as the participants with either a CR or PR or lack of response (LOR), where LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). BOR was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site.

Time frame:
From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Best Overall Response (BOR)
ParticipantsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
CR000
PR111112
LOR-U234
LOR-M210
LOR-P211
SecondaryNumber of Participants With Maximal Improvement From Baseline in Global Severity Rating (GSR) by Clinician-reported cGVHD Assessment

The GSR assessment was performed by asking the participants to rate their disease severity of cGVHD symptoms on a 0 to 10-point numeric rating scale, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. The response was defined using scores from 9 organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI) track, lower GI tract, liver, lungs, and joints and fascia plus GSR. End of treatment (EOT) visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as lowest GSR score on scheduled visits minus GSR score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms. Only those categories in which at least 1 participant had data were reported.

Time frame:
From Baseline up to end of treatment (i.e., up to 64.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Maximal Improvement From Baseline in Global Severity Rating (GSR) by Clinician-reported cGVHD Assessment
ParticipantsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
-7002
-6020
-5220
-4203
-3401
-2244
-1124
0543
1011
3010
Missing103
SecondaryNumber of Participants With Maximal Improvement From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report

cGVHD symptom severity was self-reported by participants. Participants were asked to rate their disease symptom severity over the last week on the following questions: skin itching at its worst, moth dryness at its worst, mouth pain at its worst, mouth sensitivity at its worst, main compliant on eyes, symptom severity on eyes. Severity rating was done on a 0 to 10-point numeric rating scare, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. EOT visit was performed within 3 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Maximal improvement from Baseline was calculated as the lowest symptom severity score on scheduled visits minus the symptom severity score at Baseline with possible ranges from -10 to 10. The lower the number means the better improvement in cGVHD symptoms.

Time frame:
From Baseline up to end of treatment (i.e., up to 64.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Maximal Improvement From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report
ParticipantsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
-8001
-7320
-6014
-5202
-4221
-3222
-2232
-1222
0110
1001
2012
4100
Missing224
SecondaryFailure-free Survival (FFS)

Failure-free survival was defined as the time (in months) from first dose of study drug to either the start of another new systemic treatment for cGVHD, relapse of the underlying disease or death. If no such events happened, FFS was censored by last response assessment or long term follow up assessment, whichever was the latest and available. Kaplan-Meier survival method was used for the analysis.

Time frame:
From first dose of study drug to either start of another new systemic treatment for cGVHD, relapse of the underlying disease or death or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Median · months
Failure-free Survival (FFS)
monthsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Failure-free Survival (FFS)10.6 (3.78 to NA)9.8 (4.01 to 19.02)9.7 (2.60 to 16.10)
SecondaryChange From Baseline in Corticosteroids Dose

Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

Time frame:
Baseline up to end of treatment (i.e., anytime up to 64.2 months)
Reported as:
Mean · milligrams per kilogram per day
Change From Baseline in Corticosteroids Dose
milligrams per kilogram per dayCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Change From Baseline in Corticosteroids Dose-0.110 ± 0.101-0.111 ± 0.147-0.116 ± 0.152
SecondaryNumber of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage

Calcineurin inhibitors included systemic tacrolimus and cyclosporine. Number of participants who took CNI at Baseline and had reduction and discontinuation in CNI use as compared to Baseline during the study are reported in this outcome measure. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

Time frame:
Baseline up to end of treatment (i.e., anytime up to 64.2 months)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage
ParticipantsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Participants with reduction in CNI dose556
Participants who discontinued CNI013
SecondaryDuration of Response (DOR)

The DOR was defined as the time (in weeks) from first documentation of response to the time of first documentation of deterioration from best response (e.g., CR to PR, or PR to LR). LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site. Kaplan-Meier was used for the analysis.

Time frame:
From the date of first response until documented disease progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Median · weeks
Duration of Response (DOR)
weeksCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Duration of Response (DOR)40.0 (8.14 to NA)10.9 (2.00 to 35.14)15.9 (4.14 to 38.14)
SecondaryTime-to-Response (TTR)

Time-to-response was measured as the time (in weeks) from first dose of study drug to the time of first documentation of response. Response was defined as the participants achieving a PR or CR at any post-baseline response assessment. Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site and PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
From first dose of study drug treatment to the time of first documentation of response or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Median · weeks
Time-to-Response (TTR)
weeksCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Time-to-Response (TTR)8.14 (7.9 to 26.1)8.14 (4.1 to 40.0)8.07 (4.1 to 67.0)
SecondaryPercentage of Participants With Best Response in Each Individual Organ

Best response was defined as the percentage of participants with CR or PR. Response was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site. Organ response assessment was performed on 9 individual organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, and joints and fascia and is reported in this outcome measure.

Time frame:
From date of randomization until disease progression or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Response in Each Individual Organ
percentage of participantsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Skin23.116.713.3
Eyes35.736.423.5
Mouth46.245.545.5
Esophagus50.0—25.0
Upper GI tract100.0100.050.0
Lower GI tract0100.00
Liver—50.0—
Lungs0030.0
Joints and Fascia54.545.541.7
SecondaryOverall Survival (OS)

Overall survival was defined as the time (in months) from first dose of study drug to the death due to any reason. If there was no death, OS was censored by last visit, last long-term follow-up, or study cut-off date, whichever occurred first. Kaplan-Meier survival method was used for the analysis.

Time frame:
From first dose of study drug to date of death from any cause or data cut-off, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Median · months
Overall Survival (OS)
monthsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Overall Survival (OS)NA (39.46 to NA)NA (52.07 to NA)NA (23.29 to NA)
SecondaryTime to Next Therapy (TTNT)

The TTNT was defined as the time (in months) from first treatment to the time of new systemic cGVHD treatment. TTNT was censored by last response assessment or long term follow up assessment, whichever was earlier. Kaplan-Meier survival method was used for the analysis.

Time frame:
From time of first treatment to the time of new systemic cGVHD treatment or long term follow-up assessment, whichever occurred first (maximum duration: up to 64.2 months)
Reported as:
Median · months
Time to Next Therapy (TTNT)
monthsCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Time to Next Therapy (TTNT)15.2 (5.22 to NA)9.8 (4.01 to 19.02)14.2 (2.66 to NA)
SecondaryChange From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points

Lee cGVHD symptom scale, a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing better outcome. Score for each subscale was normalized to a score ranged from 0 to 100, where higher score=worse symptoms. An overall Lee cGvHD score was calculated as average of these 7 subscales and it ranged from 0 to 100, where a higher score = worse symptoms. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

Time frame:
Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26, 27,28,29,30,31,32,33,34,35,36,37, 38,39,40,41,42,43,44,45,46,47,48, 49, 50,51,52,53, 54,55, 56, 57,58,59,60,61,62,63,67 and EOT (i.e., anytime up to 64.2 months)
Reported as:
Mean · score on a scale
Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points
score on a scaleCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Cycle 2, Day 1——-5.2 ± 6.3
Cycle 3, Day 1-3.0 ± 8.50.5 ± 7.3-4.3 ± 8.2
Cycle 4, Day 1——-2.7 ± 8.2
Cycle 5, Day 1-3.7 ± 11.0-3.7 ± 7.0-0.5 ± 10.8
Cycle 6, Day 1——-0.8 ± 9.3
Cycle 7, Day 1-4.9 ± 8.4-2.2 ± 8.8-2.0 ± 12.3
Cycle 8, Day 1—-7.1 ± 10.1-2.9 ± 10.9
Cycle 9, Day 1-3.7 ± 10.7-4.2 ± 5.5-3.6 ± 10.2
Cycle 10, Day 1—-2.7 ± 6.1-3.7 ± 9.9
Cycle 11, Day 1-3.4 ± 11.5-5.5 ± 6.0-4.5 ± 6.1
Cycle 12, Day 1-3.9 ± 8.1-7.6 ± 7.7-2.8 ± 6.0
Cycle 13, Day 1-5.8 ± 14.7-5.9 ± 8.8-0.6 ± 7.1
Cycle 14, Day 1-1.6 ± 17.1-5.0 ± 7.3-1.5 ± 7.7
Cycle 15, Day 1-4.8 ± 15.8-6.8 ± 7.0-3.2 ± 8.2
Cycle 16, Day 1-4.6 ± 16.1-6.9 ± 7.61.9 ± 7.9
Cycle 17, Day 1-4.1 ± 17.2-10.1 ± 5.50.0 ± 12.5
Cycle 18, Day 1-2.3 ± 17.6-11.5 ± 8.4-2.3 ± 7.8
Cycle 19, Day 1-7.7 ± 19.6-9.9 ± 7.8-6.6 ± 9.9
Cycle 20, Day 1-4.6 ± 22.0-9.0 ± 10.3-2.8 ± 5.6
Cycle 21, Day 1-3.1 ± 19.1-7.5 ± 10.7-4.0 ± 7.9
Cycle 22, Day 1-4.1 ± 18.9-14.5 ± 9.1-3.6 ± 5.0
Cycle 23, Day 1-4.1 ± 19.1-11.6 ± 9.3-6.2 ± 7.7
Cycle 24, Day 1-6.7 ± 21.0-18.7-5.6 ± 5.7
Cycle 25, Day 12.2 ± 18.8-12.4 ± 8.2-8.4 ± 3.4
Cycle 26, Day 11.3 ± 14.3—0.2
Cycle 27, Day 1-3.5 ± 25.3-13.2 ± 6.6-6.0 ± 9.6
Cycle 28, Day 14.4 ± 13.4—2.6
Cycle 29, Day 1-2.8 ± 23.7-11.0 ± 7.3-3.7 ± 13.0
Cycle 30, Day 19.0 ± 7.5——
Cycle 31, Day 1-4.8 ± 27.9-15.6 ± 4.3-12.9
Cycle 32, Day 110.3 ± 6.9——
Cycle 33, Day 10.5 ± 20.7-13.5 ± 9.0-12.9
Cycle 34, Day 113.5 ± 3.6——
Cycle 35, Day 1-2.5 ± 23.3-11.0 ± 12.4-12.9
Cycle 36, Day 17.5 ± 6.4——
Cycle 37, Day 1-5.3 ± 29.0-13.6 ± 8.1—
Cycle 38, Day 19.1 ± 5.2——
Cycle 39, Day 1-6.2 ± 25.9-14.3 ± 8.5-12.9
Cycle 40, Day 12.7——
Cycle 41, Day 1-25.7-19.3-12.9
Cycle 42, Day 14.6——
Cycle 43, Day 1-20.4-19.9-12.9
Cycle 44, Day 14.3——
Cycle 45, Day 1——-12.3
Cycle 46, Day 14.6——
Cycle 47, Day 1-6.8-16.8-12.9
Cycle 48, Day 12.4——
Cycle 49, Day 1—-15.4-14.3
Cycle 50, Day 14.5——
Cycle 51, Day 1-12.0—-12.9
Cycle 52, Day 16.0——
Cycle 53, Day 1-19.2——
Cycle 54, Day 14.9——
Cycle 55, Day 1-16.8——
Cycle 56, Day 11.8——
Cycle 57, Day 1-17.6——
Cycle 58, Day 15.4——
Cycle 59, Day 1-12.7——
Cycle 60, Day 14.2——
Cycle 61, Day 1-19.3——
Cycle 62, Day 14.4——
Cycle 63, Day 1-18.0——
Cycle 67, Day 1-21.9——
EOT-4.3 ± 11.7-2.4 ± 10.92.5 ± 11.9
SecondaryChange From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Each Specified Time Points

FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

Time frame:
Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27, 29,30,31,32,33,34,35,36,37,38, 39,40,41,43, 47,48,49,51,52,53, 54, 55,56, 57,58,60,61,62,63,67, EOT (i.e., anytime up to 64.2 months)
Reported as:
Mean · percent predicted FEV1
Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Each Specified Time Points
percent predicted FEV1Cohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Cycle 2, Day 1——-4.8 ± 6.7
Cycle 3, Day 11.1 ± 4.8-1.8 ± 7.1-1.5 ± 6.2
Cycle 4, Day 1——-0.2 ± 8.4
Cycle 5, Day 1-3.3 ± 8.0-5.0 ± 6.50.5 ± 5.9
Cycle 6, Day 1——-0.9 ± 6.4
Cycle 7, Day 1-3.5 ± 4.6-2.6 ± 9.4-0.9 ± 11.8
Cycle 8, Day 1—1.0-1.1 ± 8.0
Cycle 9, Day 1-1.7 ± 6.8-5.9 ± 11.7-3.0 ± 11.8
Cycle 10, Day 1—-6.0 ± 8.52.7 ± 3.9
Cycle 11, Day 1-4.3 ± 5.2-4.0 ± 8.5-4.4 ± 15.8
Cycle 12, Day 1-2.0-1.00.3 ± 3.6
Cycle 13, Day 1-5.9 ± 9.3-2.5 ± 14.7-3.5 ± 13.2
Cycle 14, Day 12.00.0-5.1 ± 9.1
Cycle 15, Day 1-6.7 ± 11.7-2.3 ± 5.1-6.1 ± 12.6
Cycle 16, Day 12.0-8.0 ± 15.6-4.5 ± 7.3
Cycle 17, Day 1-5.3 ± 9.1-6.0 ± 7.2-7.9 ± 15.5
Cycle 18, Day 1—-7.5 ± 10.64.0 ± 6.0
Cycle 19, Day 1-5.2 ± 9.9-6.3 ± 5.50.5 ± 8.5
Cycle 20, Day 1—-8.0 ± 7.14.0 ± 10.4
Cycle 21, Day 1-7.4 ± 10.60.0-10.0 ± 19.8
Cycle 22, Day 1—-11.0 ± 1.4-6.0 ± 17.0
Cycle 23, Day 1-4.3 ± 14.6-12.5 ± 4.9-4.8 ± 11.2
Cycle 24, Day 12.0-18.0-19.0
Cycle 25, Day 1-11.0 ± 15.6-12.5 ± 3.5-5.0 ± 11.4
Cycle 26, Day 10.0——
Cycle 27, Day 1-6.5 ± 13.4-17.0 ± 9.9-10.0 ± 17.0
Cycle 29, Day 1-0.5 ± 9.217.0 ± 11.30.0 ± 1.4
Cycle 30, Day 13.0——
Cycle 31, Day 1-3.5 ± 12.0-19.5 ± 10.6-4.0
Cycle 32, Day 11.0——
Cycle 33, Day 15.0 ± 5.7-1.0 ± 33.9—
Cycle 34, Day 12.0——
Cycle 35, Day 15.0 ± 0.0-2.5 ± 30.4-4.0
Cycle 36, Day 13.0—5.0
Cycle 37, Day 1-1.0-22.0—
Cycle 38, Day 11.0——
Cycle 39, Day 110.0 ± 2.8-23.0 ± 11.3-5.0
Cycle 40, Day 1-1.0——
Cycle 41, Day 115.0——
Cycle 43, Day 116.0-21.0-7.0
Cycle 47, Day 15.0—-5.0
Cycle 48, Day 13.0——
Cycle 49, Day 18.0—-2.0
Cycle 51, Day 18.0——
Cycle 52, Day 10.0——
Cycle 53, Day 19.0——
Cycle 54, Day 14.0——
Cycle 55, Day 113.0——
Cycle 56, Day 14.0——
Cycle 57, Day 113.0——
Cycle 58, Day 15.0——
Cycle 60, Day 14.0——
Cycle 61, Day 110.0——
Cycle 62, Day 12.0——
Cycle 63, Day 113.0——
Cycle 67, Day 114.0——
EOT-1.4 ± 9.0-10.1 ± 15.7-7.4 ± 14.9
SecondaryChange From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Each Specified Time Points

FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

Time frame:
Baseline, Day 1 of Cycles 2, 3,4, 5,6,7,8,9,10,11,12,13, 14,15,16,17,18,19,20,21,22,23,24,25,26, 27,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47, 48,49, 51,52,53,54, 55, 56,57,58,60,61, 62, 63,67, EOT (i.e., anytime up to 64.2 months)
Reported as:
Mean · percent predicted FVC
Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Each Specified Time Points
percent predicted FVCCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Cycle 2, Day 1——-5.5 ± 9.9
Cycle 3, Day 10.5 ± 3.8-2.4 ± 6.0-3.0 ± 6.7
Cycle 4, Day 1——-0.2 ± 8.6
Cycle 5, Day 1-0.5 ± 7.1-4.3 ± 5.21.6 ± 6.3
Cycle 6, Day 1——0.8 ± 9.5
Cycle 7, Day 1-2.9 ± 5.2-1.3 ± 6.42.3 ± 9.7
Cycle 8, Day 1—2.00.4 ± 8.9
Cycle 9, Day 10.4 ± 5.1-2.9 ± 5.5-0.8 ± 9.5
Cycle 10, Day 1—-5.0 ± 8.54.7 ± 4.9
Cycle 11, Day 1-1.1 ± 7.3-2.7 ± 5.6-4.4 ± 12.0
Cycle 12, Day 12.01.00.7 ± 5.8
Cycle 13, Day 1-2.4 ± 7.9-3.3 ± 15.4-4.9 ± 9.8
Cycle 14, Day 111.02.0-2.7 ± 7.1
Cycle 15, Day 1-3.7 ± 10.4-3.3 ± 5.5-4.8 ± 11.5
Cycle 16, Day 116.0-6.0 ± 19.8-6.5 ± 6.5
Cycle 17, Day 1-3.2 ± 6.3-3.0 ± 11.8-5.6 ± 12.8
Cycle 18, Day 1—-7.5 ± 9.24.0 ± 4.0
Cycle 19, Day 1-2.3 ± 6.8-5.3 ± 4.70.8 ± 5.1
Cycle 20, Day 1—-10.5 ± 2.1-2.0 ± 5.6
Cycle 21, Day 1-3.2 ± 8.1-3.0-6.6 ± 17.0
Cycle 22, Day 1—-11.0 ± 0.0-6.0 ± 8.5
Cycle 23, Day 10.0 ± 12.3-11.0 ± 2.8-1.8 ± 10.6
Cycle 24, Day 14.0-13.0-15.0
Cycle 25, Day 1-7.0 ± 11.3-10.5 ± 3.5-1.3 ± 11.7
Cycle 26, Day 14.0——
Cycle 27, Day 1-2.0 ± 4.2-18.0 ± 12.7-4.0 ± 21.2
Cycle 29, Day 12.5 ± 4.9-11.06.0 ± 1.4
Cycle 30, Day 14.0——
Cycle 31, Day 11.5 ± 3.5-15.5 ± 7.8-4.0
Cycle 32, Day 12.0——
Cycle 33, Day 111.0 ± 0.0-17.5 ± 7.8—
Cycle 34, Day 16.0——
Cycle 35, Day 111.0 ± 5.7-15.0 ± 11.3-3.0
Cycle 36, Day 15.0—2.0
Cycle 37, Day 17.0-24.0—
Cycle 38, Day 12.0——
Cycle 39, Day 112.5 ± 0.7-20.5 ± 12.0-1.0
Cycle 40, Day 13.0——
Cycle 41, Day 115.0——
Cycle 43, Day 117.0-18.0-4.0
Cycle 47, Day 15.0—-2.0
Cycle 48, Day 15.0——
Cycle 49, Day 16.0—2.0
Cycle 51, Day 19.0——
Cycle 52, Day 13.0——
Cycle 53, Day 18.0——
Cycle 54, Day 15.0——
Cycle 55, Day 113.0——
Cycle 56, Day 17.0——
Cycle 57, Day 114.0——
Cycle 58, Day 17.0——
Cycle 60, Day 18.0——
Cycle 61, Day 112.0——
Cycle 62, Day 15.0——
Cycle 63, Day 112.0——
Cycle 67, Day 114.0——
EOT-2.5 ± 10.3-8.4 ± 9.2-7.8 ± 14.7
SecondaryChange From Baseline in Percent Predicted Hemoglobin (HGB) Corrected Diffusing Capacity of Lung for Carbon Monoxide (DLco) at Each Specified Time Points

DLco is a measurement of the ability of the lungs to transfer gases from the air to the blood. Change from baseline in diffusing capacity of the lung for carbon monoxide (percent predicted hemoglobin level corrected) was reported for this measure. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

Time frame:
Baseline, Day 1 of Cycles 2,3,4,5,6,7,8,9,10,11,12,13, 14,15,16,17,18,19,20,21,22,23,24,25,26,27, 29,31,32,33,34,35,36,37,39,40,41,43,47,49,51,53,55, 61, 62, 63, 67, EOT (i.e., anytime up to 64.2 Months)
Reported as:
Mean · Percent Predicted HGB Corrected DLco
Change From Baseline in Percent Predicted Hemoglobin (HGB) Corrected Diffusing Capacity of Lung for Carbon Monoxide (DLco) at Each Specified Time Points
Percent Predicted HGB Corrected DLcoCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Cycle 2, Day 1——-5.243 ± 9.830
Cycle 3, Day 14.545 ± 22.991-0.638 ± 7.059-3.928 ± 9.492
Cycle 4, Day 1——0.278 ± 9.683
Cycle 5, Day 14.635 ± 23.989-4.462 ± 23.621-4.111 ± 9.138
Cycle 6, Day 1——-3.143 ± 10.385
Cycle 7, Day 11.521 ± 19.8366.184 ± 9.436-4.275 ± 11.464
Cycle 8, Day 1—3.554-3.787 ± 11.983
Cycle 9, Day 1-4.514 ± 7.4012.570 ± 8.902-2.540 ± 11.897
Cycle 10, Day 1—4.343 ± 3.1441.328 ± 8.887
Cycle 11, Day 1-0.625 ± 7.2626.582 ± 10.695-2.720 ± 10.920
Cycle 12, Day 10.5314.076-1.378 ± 6.364
Cycle 13, Day 1-5.548 ± 12.1751.882 ± 7.5222.091 ± 13.290
Cycle 14, Day 112.9160.3580.309 ± 11.651
Cycle 15, Day 10.228 ± 15.7311.125 ± 5.927-5.309 ± 11.514
Cycle 16, Day 148.465-6.618 ± 15.443-6.840 ± 15.053
Cycle 17, Day 1-1.018 ± 9.2268.458 ± 6.229-10.865 ± 13.346
Cycle 18, Day 1—15.543 ± 11.753-3.174 ± 3.106
Cycle 19, Day 1-2.293 ± 5.7631.824 ± 8.539-2.020 ± 2.436
Cycle 20, Day 1—-14.692-13.517 ± 5.936
Cycle 21, Day 1-2.778 ± 8.187-10.661-12.354 ± 12.800
Cycle 22, Day 1—3.347 ± 3.560-17.222 ± 16.947
Cycle 23, Day 10.354 ± 1.844-15.184 ± 20.181-2.219 ± 10.614
Cycle 24, Day 16.945-18.095-11.430
Cycle 25, Day 1-4.461 ± 19.8656.289 ± 2.469-13.392
Cycle 26, Day 14.715——
Cycle 27, Day 1-8.047 ± 24.788-9.914 ± 15.387-11.154
Cycle 29, Day 1-6.701 ± 1.671-18.814 ± 24.9608.613
Cycle 31, Day 12.343 ± 20.988-0.800 ± 17.52810.833
Cycle 32, Day 15.586——
Cycle 33, Day 19.901 ± 9.954-5.962 ± 10.550—
Cycle 34, Day 14.863——
Cycle 35, Day 113.867 ± 1.309-0.426 ± 6.6775.088
Cycle 36, Day 14.166—10.372
Cycle 37, Day 19.306-19.228—
Cycle 39, Day 114.754 ± 0.649-6.813 ± 12.8105.902
Cycle 40, Day 15.586——
Cycle 41, Day 122.884——
Cycle 43, Day 115.2138.77516.351
Cycle 47, Day 19.660——
Cycle 49, Day 1-3.599——
Cycle 51, Day 111.734——
Cycle 53, Day 110.292——
Cycle 55, Day 116.550——
Cycle 61, Day 117.682——
Cycle 62, Day 14.170——
Cycle 63, Day 126.215——
Cycle 67, Day 141.384——
EOT-1.962 ± 11.4260.985 ± 5.919-10.371 ± 14.208
SecondaryChange From Baseline in Percent Predicted Total Lung Capacity (TLC) at Each Specified Time Points

TLC is the volume of air in the lungs upon the maximum effort of inspiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

Time frame:
Baseline, Day 1 of Cycles 2,3, 4, 5,6,7, 8, 9, 10,11,12,13, 14, 15, 16, 17, 18, 19, 20,21, 22,23,24, 25, 26, 27,29, 30, 31,32, 33, 34, 35,36, 37, 38,39, 40,41,43,47, 48, 49,51,52,53, 54,55,56,57,58, 60,61,62, 63, 67, EOT (i.e., anytime up to 64.2 Months)
Reported as:
Mean · Percent Predicted TLC
Change From Baseline in Percent Predicted Total Lung Capacity (TLC) at Each Specified Time Points
Percent Predicted TLCCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Cycle 2, Day 1——-9.0 ± 13.4
Cycle 3, Day 11.6 ± 11.91.9 ± 8.5-0.6 ± 14.8
Cycle 4, Day 1——3.3 ± 14.0
Cycle 5, Day 1-2.6 ± 16.8-7.2 ± 10.5-1.7 ± 11.2
Cycle 6, Day 1——-4.4 ± 11.6
Cycle 7, Day 1-3.7 ± 6.6-4.4 ± 6.3-2.6 ± 13.4
Cycle 8, Day 1—-5.0-0.2 ± 12.9
Cycle 9, Day 1-2.9 ± 6.1-6.0 ± 8.5-0.9 ± 15.8
Cycle 10, Day 1—-18.5 ± 6.43.6 ± 14.7
Cycle 11, Day 10.7 ± 4.3-5.2 ± 11.2-3.0 ± 19.7
Cycle 12, Day 1-9.00.0-8.0 ± 14.2
Cycle 13, Day 1-0.3 ± 7.1-10.3 ± 18.7-3.3 ± 17.6
Cycle 14, Day 123.0-7.0-5.8 ± 16.5
Cycle 15, Day 1-2.8 ± 10.8-1.0 ± 5.6-7.0 ± 12.0
Cycle 16, Day 1-3.0-14.0 ± 12.7-15.5 ± 9.5
Cycle 17, Day 1-3.0 ± 6.2-17.0 ± 11.4-18.1 ± 15.6
Cycle 18, Day 1—-16.0 ± 8.50.0 ± 13.9
Cycle 19, Day 1-4.6 ± 6.1-7.7 ± 10.5-7.0 ± 5.4
Cycle 20, Day 1—-9.5 ± 16.3-9.3 ± 15.4
Cycle 21, Day 10.3 ± 9.3-18.0-14.4 ± 24.0
Cycle 22, Day 1—-18.5 ± 6.4-21.0 ± 14.1
Cycle 23, Day 10.0 ± 8.7-21.0 ± 19.8-2.8 ± 18.8
Cycle 24, Day 10.0-15.0-34.0
Cycle 25, Day 1-3.0 ± 7.1-19.5 ± 13.4-6.3 ± 24.1
Cycle 26, Day 10.0——
Cycle 27, Day 15.5 ± 16.3-24.0 ± 12.7-14.5 ± 24.7
Cycle 29, Day 1-1.0 ± 17.0-27.5 ± 21.912.0 ± 14.1
Cycle 30, Day 17.0——
Cycle 31, Day 17.5 ± 17.7-36.017.0
Cycle 32, Day 11.0——
Cycle 33, Day 114.0 ± 11.3-39.0—
Cycle 34, Day 12.0——
Cycle 35, Day 110.5 ± 7.8-23.5 ± 16.313.0
Cycle 36, Day 16.0—-6.0
Cycle 37, Day 1-7.0-41.0—
Cycle 38, Day 12.0——
Cycle 39, Day 124.0 ± 28.3-30.0 ± 21.223.0
Cycle 40, Day 10.0——
Cycle 41, Day 138.0——
Cycle 43, Day 133.0-16.021.0
Cycle 47, Day 119.0—25.0
Cycle 48, Day 1-13.0——
Cycle 49, Day 15.0—1.0
Cycle 51, Day 115.0——
Cycle 52, Day 11.0——
Cycle 53, Day 115.0——
Cycle 54, Day 14.0——
Cycle 55, Day 129.0——
Cycle 56, Day 19.0——
Cycle 57, Day 118.0——
Cycle 58, Day 15.0——
Cycle 60, Day 1-3.0——
Cycle 61, Day 15.0——
Cycle 62, Day 1-1.0——
Cycle 63, Day 112.0——
Cycle 67, Day 112.0——
EOT5.2 ± 27.5-2.4 ± 15.0-12.6 ± 20.1
SecondaryChange From Baseline in Percent Predicted Residual Volume (RV) at Each Specified Time Points

RV is the volume of air remaining in the lungs after maximum forceful expiration. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 3 days after the participant's last dose of study drug.

Time frame:
Baseline, Day 1 of Cycles 2, 3, 4,5, 6,7, 8, 9, 10, 11,12, 13, 14,15, 16,17, 18, 19,20, 21,22,23, 24, 25, 26,27, 29, 30, 31, 32, 33,34, 35,36, 37,38, 39, 40,41, 43,47, 48, 49,51,52,53, 54, 55,56,57, 58,60,61,62,63,67, EOT (i.e., anytime up to 64.2 Months)
Reported as:
Mean · percent predicted RV
Change From Baseline in Percent Predicted Residual Volume (RV) at Each Specified Time Points
percent predicted RVCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Cycle 2, Day 1——-18.0 ± 30.1
Cycle 3, Day 10.2 ± 22.2-4.6 ± 18.89.0 ± 34.4
Cycle 4, Day 1——17.8 ± 29.0
Cycle 5, Day 15.2 ± 24.5-11.5 ± 26.9-3.7 ± 29.8
Cycle 6, Day 1——-10.9 ± 37.5
Cycle 7, Day 14.9 ± 29.1-9.9 ± 17.1-7.5 ± 33.0
Cycle 8, Day 1—-28.02.5 ± 39.7
Cycle 9, Day 16.4 ± 27.4-19.9 ± 24.30.1 ± 35.6
Cycle 10, Day 1—-47.5 ± 0.71.4 ± 38.2
Cycle 11, Day 122.1 ± 29.6-10.5 ± 28.35.4 ± 38.0
Cycle 12, Day 1-28.0-5.0-22.2 ± 49.9
Cycle 13, Day 120.3 ± 19.9-27.0 ± 35.60.3 ± 32.6
Cycle 14, Day 178.0-31.0-6.5 ± 36.3
Cycle 15, Day 120.3 ± 27.4-0.7 ± 18.1-16.7 ± 22.3
Cycle 16, Day 10.0-36.5 ± 13.4-27.5 ± 31.9
Cycle 17, Day 113.6 ± 27.8-47.3 ± 25.1-39.1 ± 26.2
Cycle 18, Day 1—-42.0 ± 0.0-7.3 ± 33.7
Cycle 19, Day 15.4 ± 28.7-19.7 ± 18.0-23.5 ± 18.7
Cycle 20, Day 1—-7.5 ± 37.5-22.0 ± 44.3
Cycle 21, Day 18.3 ± 10.0-44.0-30.2 ± 51.2
Cycle 22, Day 1—-33.0 ± 19.8-41.0 ± 46.7
Cycle 23, Day 10.3 ± 5.1-72.01.5 ± 44.8
Cycle 24, Day 1-4.0-17.0-78.0
Cycle 25, Day 11.0 ± 9.9-34.0 ± 31.1-23.3 ± 56.0
Cycle 26, Day 1-3.0——
Cycle 27, Day 119.5 ± 41.7-39.5 ± 20.5-41.0 ± 28.3
Cycle 29, Day 1-13.0 ± 42.4-13.017.5 ± 40.3
Cycle 30, Day 121.0——
Cycle 31, Day 115.0 ± 43.8-93.061.0
Cycle 32, Day 15.0——
Cycle 33, Day 114.5 ± 36.1-70.0—
Cycle 34, Day 1-1.0——
Cycle 35, Day 13.5 ± 36.1-34.5 ± 33.247.0
Cycle 36, Day 117.0—-20.0
Cycle 37, Day 1-54.0-70.0—
Cycle 38, Day 18.0——
Cycle 39, Day 143.0 ± 89.1-43.0 ± 42.481.0
Cycle 40, Day 1-1.0——
Cycle 41, Day 180.0——
Cycle 43, Day 158.0-26.075.0
Cycle 47, Day 142.0—87.0
Cycle 48, Day 1-50.0——
Cycle 49, Day 1-14.0—-5.0
Cycle 51, Day 122.0——
Cycle 52, Day 1-4.0——
Cycle 53, Day 122.0——
Cycle 54, Day 14.0——
Cycle 55, Day 153.0——
Cycle 56, Day 117.0——
Cycle 57, Day 118.0——
Cycle 58, Day 14.0——
Cycle 60, Day 1-20.0——
Cycle 61, Day 1-18.0——
Cycle 62, Day 1-8.0——
Cycle 63, Day 16.0——
Cycle 67, Day 12.0——
EOT6.3 ± 24.310.6 ± 34.9-18.5 ± 32.6
SecondaryPharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)

Cmax was the maximum observed plasma concentration, obtained by a non-compartmental analysis. Cmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.

Time frame:
Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1
Reported as:
Geometric mean · nanograms per milliliter
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)
nanograms per milliliterCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Belumosudil: Cycle 1 Day 12500 ± 60.11400 ± 98.52960 ± 69.7
Belumosudil: Cycle 2 Day 12020 ± 1011890 ± 1203270 ± 63.0
KD025m1: Cycle 1 Day 144.4 ± 67.934.8 ± 58.863.9 ± 59.4
KD025m1: Cycle 2 Day 136.2 ± 43.045.0 ± 38.655.8 ± 82.1
KD025m2: Cycle 1 Day 1208 ± 93.199.2 ± 112388 ± 82.3
KD025m2: Cycle 2 Day 1158 ± 150145 ± 147265 ± 154
SecondaryPharmacokinetics: Time of the Maximum Observed Plasma Concentration (Tmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)

Tmax was defined as time to reach maximum observed plasma concentration, obtained by a non-compartmental analysis. Tmax data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.

Time frame:
Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1
Reported as:
Median · hours
Pharmacokinetics: Time of the Maximum Observed Plasma Concentration (Tmax) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)
hoursCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Belumosudil: Cycle 1 Day 12.12 (0.98 to 5.00)3.43 (1.97 to 6.00)3.03 (1.85 to 6.00)
Belumosudil: Cycle 2 Day 12.53 (0 to 4.87)2.47 (0 to 5.83)2.66 (1.00 to 6.02)
KD025m1: Cycle 1 Day 12.50 (1.00 to 3.98)1.75 (1.08 to 5.95)1.98 (0.90 to 4.95)
KD025m1: Cycle 2 Day 12.98 (1.17 to 3.03)2.05 (1.08 to 5.83)2.17 (1.00 to 4.03)
KD025m2: Cycle 1 Day 12.82 (1.93 to 5.00)3.00 (2.00 to 6.00)2.98 (1.85 to 6.00)
KD025m2: Cycle 2 Day 12.98 (0 to 3.93)2.00 (1.05 to 5.07)3.03 (1.98 to 6.02)
SecondaryPharmacokinetics: The Area Under the Plasma Concentration Versus Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6hr) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)

AUC0-6hr was defined as area under the plasma concentration versus time curve from time 0 to 6 hours post-dose, obtained by a non-compartmental analysis from the concentration-time data. AUC0-6hr data for Belumosudil and its metabolites KD025m1 and KD025m2 are reported in this outcome measure.

Time frame:
Cycles 1 and 2: pre-dose (0 hour), 1, 2, 3, 4, 5, and 6 hours post-dose on Day 1
Reported as:
Geometric mean · hours*nanograms per milliliter
Pharmacokinetics: The Area Under the Plasma Concentration Versus Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6hr) of Belumosudil and Its Metabolites (KD025m1 and KD025m2)
hours*nanograms per milliliterCohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QD
Belumosudil: Cycle 1 Day 18350 ± 60.34960 ± 10811500 ± 97.3
Belumosudil: Cycle 2 Day 17090 ± 95.97190 ± 11512000 ± 68.8
KD025m1: Cycle 1 Day 1140 ± 72.3114 ± 60.8216 ± 61.9
KD025m1: Cycle 2 Day 1123 ± 38.2160 ± 31.3178 ± 72.9
KD025m2: Cycle 1 Day 1565 ± 90.8282 ± 1251150 ± 97.1
KD025m2: Cycle 2 Day 1471 ± 145513 ± 122923 ± 144

Adverse events

Collected over From first dose of study drug up to 28 days after the last dose of study drug (maximum duration: up to 64.2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 200 mg QD5/17 (29.4%)5/17 (29.4%)17/17 (100%)
Cohort 2 200 mg BID5/16 (31.3%)6/16 (37.5%)16/16 (100%)
Cohort 3 400 mg QD9/21 (42.9%)13/21 (61.9%)19/21 (90.5%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventCohort 1 200 mg QDCohort 2 200 mg BIDCohort 3 400 mg QD
PneumoniaInfections and infestations1/171/163/21
DyspnoeaRespiratory, thoracic and mediastinal disorders0/171/163/21
Influenza like illnessGeneral disorders0/170/162/21
HypoxiaRespiratory, thoracic and mediastinal disorders0/170/162/21
Non-cardiac chest painGeneral disorders0/171/160/21
Chronic graft versus host disease in skinImmune system disorders0/171/160/21
BacteraemiaInfections and infestations0/171/160/21
CellulitisInfections and infestations0/171/160/21
Citrobacter infectionInfections and infestations0/171/160/21
Stenotrophomonas infectionInfections and infestations0/171/160/21
Most frequent other events
Showing 10 of 205
Most frequent other events
EventCohort 1 200 mg QDCohort 2 200 mg BIDCohort 3 400 mg QD
Upper respiratory tract infectionInfections and infestations9/179/167/21
FatigueGeneral disorders6/173/1610/21
NauseaGastrointestinal disorders6/174/169/21
DiarrhoeaGastrointestinal disorders6/175/167/21
Alanine aminotransferase increasedInvestigations6/173/162/21
CoughRespiratory, thoracic and mediastinal disorders1/174/167/21
DyspnoeaRespiratory, thoracic and mediastinal disorders2/175/166/21
AnaemiaBlood and lymphatic system disorders5/174/160/21
Aspartate aminotransferase increasedInvestigations5/172/161/21
HypertensionVascular disorders5/172/164/21

Baseline characteristics

Analysis was performed on modified intent-to-treat (mITT) population which included all participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Cohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QDTotal
Median50.0 (20 to 63)55.0 (30 to 75)46.0 (25 to 75)51.5 (20 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QDTotal
Female47920
Male1391234
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Belumosudil 200 mg QDCohort 2: Belumosudil 200 mg BIDCohort 3: Belumosudil 400 mg QDTotal
American Indian or Alaska Native0202
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0022
White15141948
More than one race0000
Unknown or Not Reported2002
08

Study locations

7 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • Sarah Cannon Research Institute at Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Texas Transplant Institute
    San Antonio, Texas 78229, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Lee SJ, Cutler C, Blazar BR, Tu A, Yang Z, Pavletic SZ. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies. Transplant Cell Ther. 2022 Oct;28(10):700.e1-700.e6. doi: 10.1016/j.jtct.2022.06.020. Epub 2022 Jul 1. PubMed 35781099 ↗
  • Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021 Jun 10;39(17):1888-1898. doi: 10.1200/JCO.20.02754. Epub 2021 Apr 20. PubMed 33877856 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in May 2022, 67 months.

Results were first posted in Jun 2023, 1 year 1 month after primary completion.

Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2016
First posted
Jul 22, 2016
StartActual
Sep 15, 2016
Primary completionActual
May 12, 2022
CompletionActual
May 12, 2022
Results first posted
Jun 28, 2023
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02841995
Responsible party
Sponsor
First posted
Jul 22, 2016
Start date
Sep 15, 2016
Primary completion
May 12, 2022
Completion
May 12, 2022
Results posted
Jun 28, 2023
Last update
Jun 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion